| Ytd | 9.70% | |
| 1y | -53.27% |
| Open | 0.24 | Prev Close | 0.23 | Low | 0.23 | High | 0.24 | Mkt Cap | 8.21M |
| Vol | 245.92K | Avg Vol | 7.62M | EPS | -0.58 | P/E | -0.40 | Forward P/E | -0.07 |
| Beta | 1.09 | Short Ratio | 0.03 | Inst. Own | 21.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.27 | 200-d Avg | 0.26 | 1yr Est | 90.50 |
Trial is entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial ev
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1